linjc16/ctgov huggingface dataset:
Effects of Dexmedetomidine on Oxygenation and Lung Mechanics in Morbidly Obese Patients Undergoing Bariatric Operations

Study Overview
=================
Brief Summary
-----------------
The study aims to investigate the effect of dexmedetomidine on oxygenation and lung mechanics in morbidly obese patients

Detailed Description
-----------------
The patients of interest are morbid obese patients scheduled for bariatric surgery. Dexmeditomidine will be infused intraoperatively after induction of anesthesia. lung mechanics (dead space and compliance) as well as oxygenation (PF ratio) will be monitored intraoperatively and postoperatively

Official Title
-----------------
Effects of Dexmedetomidine on Oxygenation and Lung Mechanics in Morbidly Obese Patients Undergoing Bariatric Operations: A Randomized Controlled Trial

Conditions
-----------------
Restrictive Lung Disease

Intervention / Treatment
-----------------
* Drug: Dexmedetomidine
* Drug: Normal saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Morbid obese (body mass index > 40) with documented restrictive lung disease scheduled to bariatric operation. Exclusion Criteria: Heart failure ِِِِArrhythmia Heart block Severe liver or kidney impairment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Dexmedetomidine group<br>Patients will receive either, Dexmedetomidine (Precedex, Hospira, Lake forest, IL, USA) in a dose of (1ug/Kg LBW) bolus followed by 0.5ug/Kg continuous infusion for one hour | Drug: Dexmedetomidine<br>* Dexmedetomidine infusion was previously reported to improve oxygenation and lung dynamics in patients with obstructive lung diseases. In our study we are going to investigate its effect on oxygenation and lung dynamics in restrictive lung disease<br>* Other names: Precedex;|
| Placebo Comparator: Control group<br>Patients will receive normal saline | Drug: Normal saline<br>* Normal saline<br>* Other names: Saline;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oxygenation | assessed by P/F ratio | 2 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lung mechanics | lung compliance and dead space | 2 hours | 
| arterial blood pressure | arterial blood pressure measured in mmHg | 2 hours | 
| plateau airway pressure | plateau airway pressure measured in cmH2o | 2 hours | 
| heart rate | number of heart beats per minute | 2 hours |
Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD

Study Overview
=================
Brief Summary
-----------------
Phase II efficacy evaluation, phase I/II efficacy and toxicity trial of recombinant human keratinocyte growth factor for the treatment of steroid refractory gastrointestinal graft versus host disease.

Detailed Description
-----------------
There are two processes that cause diarrhea as the clinical manifestation of graft versus host disease. The first is the obvious immunologic attack on the colonic epithelium of the recipient. Once this immunologic attack has been abated the recipient is left with a colonic mucosa that is devoid of microvilli and has a smooth intestinal boarder. This is frequently subject to superinfections from bacteria all of which cause the diarrhea to continue. Researchers only endpoint to measure clinical response of immunosuppression is the resolution of diarrhea. The human recombinant keratinocyte growth factor stimulates the growth of colonic epithelium. The growth of colonic epithelium will in turn probably ameliorate some of the diarrhea associated with graft versus host disease.

Official Title
-----------------
A Phase I/II Trial of Recombinant Human Keratinocyte Growth Factor (rHuKFG) for the Treatment of Steroid Refractory Gastrointestinal Acute Graft-versus-host Disease (aGvHD)

Conditions
-----------------
Acute Graft Versus Host Disease

Intervention / Treatment
-----------------
* Drug: Recombinant Human Keratinocyte Growth Factor


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Patients post allogeneic bone marrow transplant with watery diarrhea progressed on 2mg/kg of steroids after 3 days or failed to improve after 5 days. Patients may have skin or liver involvement with graft versus host disease. Patients should not have any infections etiology for diarrhea. Exclusion criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: aGvHD<br> | Drug: Recombinant Human Keratinocyte Growth Factor<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants with resolution of diarrhea |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute Graft Versus Host Disease, Refractory
Female Patient Preferences Regarding Physician Gender

Study Overview
=================
Brief Summary
-----------------
This is a cross sectional survey study to describe female patient preferences when choosing their OB/GYN and other providers.

Detailed Description
-----------------
The American College of Obstetricians and Gynecologists (ACOG) published that as of 2009, 79.7% of the Obstetrics and Gynecology residents were female. Given the striking decline in male providers selecting OB/GYN in more recent years, it is critical to characterize patient preferences in the current environment. Nevertheless, it is not clear that females have strong preferences regarding gender. We hope to better understand the influence of bias on physician gender in present day. The purpose of this study is to describe female population preference based on physician gender and specialty. The study will be conducted on an online platform distributed across the United States by the aid of SurveyMonkey® .

Official Title
-----------------
Female Patient Preferences Regarding Physician Gender; is There a Difference? A National Survey

Conditions
-----------------
Female Patient Preference

Participation Criteria
=================
Eligibility Criteria
-----------------
Exclusion Criteria: Unwillingness to participate in the study Lack of access to the internet Non-English speaking

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of Female Respondents Having Their Preferences Based on Physician Gender for the OB/GYN Care | Proportion of female respondents whose responses are Male physician or Female physician over No preference for the question 15, For my obstetrician/gynecologist, overall I would prefer a... | During a 10 minute period of completing the survey electronically | 
| Proportion of Female Respondents Having Their Preferences Based on Physician Gender for the Primary Care Physician | Proportion of female respondents whose responses are Male physician or Female physician over No preference for the question 16, For my primary care physician, overall I would prefer a... | During a 10 minute period of completing the survey electronically |
The Tetrad BMI, Leptin, Leptin/Adiponectin (L/A) Ratio and CA-15-3 is a Reliable Biomarker of Breast Cancer

Study Overview
=================
Brief Summary
-----------------
Objective: Evaluate body mass index (BMI), leptin, Leptin/adiponectin (L/A) ratio and cancer antigen (CA) 15-3 together as reliable biomarkers for breast cancer. Patients: Consecutive patients aged between 40 - 60 years, with breast disease and informed consent. Interventions: Patients' Anthropometric and laboratorial characteristics classified by BMI in the group of cancer and patients with benign breast disease as well as biochemical tests of leptin, adiponectin,CA 15-3, hemoglobin, glucose low-density lipoprotein cholesterol (LDLC), high-density lipoprotein cholesterol (HDLC) levels were obtained as well as a blood sample to analyze CA 15-3 levels with a electrochemiluminescence immunoassay. Hypothesis: Using together leptin, L/A ratio, CA 15-3 and BMI could offer a reliable approach to detect high risk women to develop breast cancer.

Detailed Description
-----------------
Serum levels of leptin, adiponectin and CA 15-3, as well as anthropometric and biochemical parameters were analyzed in 88 female patients attending mammography study. Predictive values of BMI, leptin, L/A ratio and CA 15-3 were determined with 95% confidence interval (CI).

Official Title
-----------------
Phase 1. Collect Samples of Breast Biopsy Patients Treated at the Hospital Radiology Service Maternal Perinatal Monica Pretelini

Conditions
-----------------
Female Breast Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female patients attending mammography, average age of the fourth and fifth decades. Exclusion Criteria: Patients with hormonal therapy.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| breast cancer patients (cases)<br>36 subjects | |
| controls<br>36 subjects | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
biomarker, BMI, breast cancer, CA-15-3, leptin
Analgesic Effect of Intravenous Patient-Controlled Analgesia (IV PCA) Versus Paravertebral Block After Video Assisted Thoracic Surgery (VATS)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the analgesic effect of paravertebral block with that of intravenous patient-controlled analgesia after video assisted thoracic surgery.

Official Title
-----------------
A Comparison Between the Analgesic Effect of Intravenous Patient-controlled Analgesia and of Paravertebral Block After Video Assisted Thoracoscopic Surgery

Conditions
-----------------
Postoperative Pain After Video Assisted Thoracic Surgery

Intervention / Treatment
-----------------
* Procedure: paravertebral block
* Procedure: PCA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients receiving video assisted thoracic surgery Exclusion Criteria: patients with cardiovascular disease patients with neurologic disease patients with contraindications to paravertebral block or epidural block patients with history of previous VATS patients with pain at the expected incision site

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PVB<br>Postoperative pain is controlled with local analgesics delivered via PVB. | Procedure: paravertebral block<br>* Postoperative pain is controlled with local analgesics via PVB.<br>|
| Active Comparator: PCA<br>Postoperatve pain is controlled with intravenous PCA. | Procedure: PCA<br>* Postoperative pain is controlled with intravenous PCA.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| severity of acute postoperative pain when moving |  | 24 hours after VATS |
fMRI Study Comparing BOLD Activation Patterns Using GW679769 In Subjects With Social Anxiety Disorder

Study Overview
=================
Brief Summary
-----------------
Evidence suggests the use of neuroimaging to detect therapeutic effects of anxiolytic treatment when appropriate cognitive-emotional tasks are use to activate the emotional brain neurocircuitry believed to be involved in the core symptoms of the disease.

Official Title
-----------------
A Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Parallel Group, fMRI Study Comparing BOLD Activation Patterns Before and After 12 Weeks of Treatment With Placebo, Comparator and GW679769 in Subjects With Social Anxiety Disorder (SAD).

Conditions
-----------------
Social Anxiety Disorder

Intervention / Treatment
-----------------
* Drug: GW679769


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Primary diagnosis of Social Anxiety Disorder. Willing to restrict alcohol to a limited intake. Exclusion criteria: History of schizophrenia, schizoaffective disorder or a bipolar disorder. Left-handed. Suffer from claustrophobia. Any reason why subject could not go into the fMRI, for example have metal implants.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: GW679769|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in images of the brain, when stimulated, after once daily dosing for 12 weeks with GW679769, comparator or placebo in subjects with SAD. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood levels of GW679769 and comparator at the Week 1 and Week 12 Change in clinical rating scales from baseline to Week 12 Safety & tolerability |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
fMRI placebo GW679769 Social Anxiety Disorder SAD
Body Composition Assessment in Healthy Full-term Neonates by Anthropometry, Air Displacement Plethysmography and Multiple-frequency Bio-impedance Analysis

Study Overview
=================
Brief Summary
-----------------
Low birth weight and prematurity are associated with adverse metabolic outcome in adult life. Yet it remains to be determined whether this outcome is the consequence of the low birth weight per se, or of the catch up growth achieved in Neonatology units using an early, 'aggressive' nutritional management. As a matter of fact, 'aggressive' nutrition may promote fat mass, rather than lean body mass accretion. Assessment of body composition therefore is key to evaluate the efficacy of the nutritional management of these infants. Scarce data is, however, available in the literature about the body composition of healthy full-term neonates in the first few days of life. The aim of this study is to: Evaluate the feasibility and reproducibility of a safe and non invasive method of measurement of infant body composition by Air Displacement Plethysmography (PeaPod). Anthropometry and BIA will be used as the reference techniques to assess the accuracy of the PeaPod Describe the body composition (fat mass, fat free mass) of healthy full-term neonates in the first few weeks of life Obtain data on the total body water content of healthy full term infants from BIA.

Official Title
-----------------
Body Composition Assessment in Healthy Full-term Neonates by Anthropometry, Air Displacement Plethysmography (PeaPod) and Multiple-frequency Bio-impedance Analysis (BIA)

Conditions
-----------------
Neonates

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Full-term infants 10th percentile for gestational age, according to the Audipog's growth chart Exclusion Criteria: Congenital diseases Chromosomal abnormalities Any disease requiring intensive care

Ages Eligible for Study
-----------------
Maximum Age: 1 Day

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy and reproducibility of the PeaPod compared with Anthropometry and BIA. We defined that assessments are convergent if the difference between methods is less than 10 percent. |  | August 2009 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Describe the body composition (fat mass, fat free mass) of healthy full-term neonates To get data on the total body water that we can refer to from BIA. |  | August 2009 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PeaPod, Anthropometry, Body Composition, Fat Mass, Total Body Water, Neonatology, BIA
Influence of Angiotensin Converting Enzyme (ACE) Genotype on Lung Diffusion in Heart Failure

Study Overview
=================
Brief Summary
-----------------
In patients with chronic heart failure ACE-inhibitor treatment improves lung diffusion and prevents pulmonary edema after fluid overload. In the western country, 3 population types of ACE genotypes exist (DD, ID, II). It is unknown whether the ACE genotype influences the response to fluid overload in ACE-inhibitor treated chronic heart failure patients.

Detailed Description
-----------------
Patients with chronic heart failure in stable clinical condition treated with ACE-inhibitors, but not aspirin, will be evaluated by means of maximal cardiopulmonary exercise test and lung function including lung diffusion measurements. These tests will be done before and after rapid 500 ml isotonic saline infusion. Patients will be grouped according to their ACE genotype.

Official Title
-----------------
Influence of ACE Genotype on Lung Diffusion at Rest and After Fluid Overload in Heart Failure Patients Treated With ACE-inhibitors

Conditions
-----------------
Heart Failure, Congestive

Intervention / Treatment
-----------------
* Drug: isotonic saline infusion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: New York Heart Association (NYHA) class I and II heart failure Chronic ACE-inhibitor treatment Exclusion Criteria: Aspirin treatment in the previous 2 months

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CMPD patients<br>Patients with CMPD with evaluation of ACE I/D polymorphism | Drug: isotonic saline infusion<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Possible identification of a genetic pattern responsible for different responses to ACE-inhibition during fluid overload in heart failure |  | Third day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Influence of ACE-genotype on exercise capacity |  | Third day | 
| Influence of ACE-genotype on lung function |  | Third day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Heart failure, pulmonary edema, ACE-inhibitors, lung diffusion, exercise capacity, Chronic heart failure
Effect of Structured Education to Decrease Blood Pressure for Hypertension in Elderly

Study Overview
=================
Brief Summary
-----------------
There is a structured educational effect on blood pressure reduction in elderly hypertensive patients.

Detailed Description
-----------------
Eligibility criteria are men and women over 60 years old and available to participate in the study for 3 months with blood pressure higher than 140/90. Exclusion criteria are severe dementia, malignant hypertension, depression Outcome measures are systolic and diastolic blood pressure after 3 months administration of structured education once a month.

Official Title
-----------------
Effect of Structured Education to Decrease Blood Pressure for Hypertension in Elderly : a Randomized Controlled Trial

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Other: Structured education
* Other: Checklist
* Other: Without structure education with checklist


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject with age more than 60 years Blood pressure higher than 140/90 Exclusion Criteria: Severe Dementia Depression Malignant Hypertension

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Structured education & checklist<br>Formatted education and checklist every month for 3 months | Other: Structured education<br>* Formatted education about hypertension<br>Other: Checklist<br> <br> |
| Active Comparator: Structured education<br>Formatted education every month for 3 months | Other: Structured education<br>* Formatted education about hypertension<br>|
| Active Comparator: Without Structured Education with checklist<br>No structured education with checklist | Other: Without structure education with checklist<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Systolic blood pressure | We aim to measure the difference in systolic blood pressure after 3 months administration structured education in elderly with hypertension | 3 Months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diastolic blood pressure | We measure the difference of diastolic blood pressure after 3 Months administration of structured education in elderly with hypertension | 3 Months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypertension